[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shanghai Institute of Acupuncture, Moxibustion and Meridian\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":146},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,70,98,122],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100636797","pterygopalatine-ganglion-stimulation-for-the-treatment-of-geographic-atrophy-100636797",false,"NCT07570355","Pterygopalatine Ganglion Stimulation for the Treatment of Geographic Atrophy","Feasibility and Safety Evaluation of Pterygopalatine Ganglion Stimulation in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Controlled Pilot Study","Inclusion Criteria:\n\n* Best-corrected visual acuity (BCVA), as measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart, ranging from 25 to 80 letters (Snellen equivalent, 20\u002F320 to 20\u002F25).\n* A confirmed diagnosis of geographic atrophy (GA) secondary to age-related macular degeneration (AMD), with no involvement of the foveal center. Fundus autofluorescence (FAF) imaging must demonstrate a total GA area of 2.5 to 17.5 mm² located within a 30° field centered on the fovea, with the presence of any pattern of increased autofluorescence at the junctional zone of GA. In cases of multifocal GA, at least one lesion must be ≥1.25 mm² in size.\n\n  * If both eyes meet the eligibility criteria, the eye with the worse BCVA will be selected as the study eye. If BCVA is equal in both eyes, the right eye will be designated as the study eye.\n\nExclusion Criteria:\n\n* History or evidence of submacular surgery or other treatments for AMD in the study eye, with the exception of oral vitamin and mineral supplementation.\n* History of intraocular surgery within 3 months prior to screening, or the presence of ocular conditions requiring surgical intervention during the study period.\n* Receipt of any periocular or intravitreal injection therapy in the study eye within 3 months prior to screening.\n* History or evidence of choroidal neovascularization in either eye, or the presence of any other retinal disease that may confound the assessment of macular structure or function (e.g., diabetic retinopathy or pathologic myopia).\n* Presence of severe systemic disease or any other condition deemed unsuitable for study participation.\n* Inability to comply with scheduled visits or complete study procedures due to cognitive impairment or other factors, as judged by the investigator.","ALL","50 Years","80 Years",{"count":20,"type":21},62,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to evaluate the feasibility and safety of pterygopalatine ganglion (PPG) stimulation in adults with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).\n\nThe main questions it aims to answer are:\n\nIs PPG stimulation feasible to implement, as reflected by participant adherence to the intervention and completion of follow-up assessments? Is PPG stimulation safe, as assessed by the incidence of adverse events and clinical ophthalmic examinations? What are the preliminary effects of PPG stimulation on choroidal perfusion, retinal sensitivity, visual acuity, and the progression of GA lesion area?\n\nResearchers will compare active PPG stimulation with sham stimulation (a procedure that mimics the intervention without delivering real stimulation) to assess feasibility and safety, while exploring potential therapeutic effects.\n\nParticipants will:\n\nReceive active or sham PPG stimulation according to randomization over a 12-month study period Attend scheduled clinic visits for safety monitoring and multimodal ophthalmic assessments Undergo examinations including optical coherence tomography (OCT), fundus autofluorescence imaging, microperimetry, and visual acuity testing",[27],"Geographic Atrophy",[27,29,30,31,32],"Pterygopalatine Ganglion","Sphenopalatine Ganglion","Clinical Trial","Age-related Macular Degeneration","NOT_YET_RECRUITING","2026-04-29",{"date":36,"type":37},"2026-05-06","ACTUAL",{"date":39,"type":21},"2026-06-01",{"date":41,"type":21},"2028-07-31",{"name":43,"class":44},"Shanghai Institute of Acupuncture, Moxibustion and Meridian","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":45},"100558587","acupuncture-reduces-relapse-in-patients-with-crohns-disease-a-superiority-trial-100558587","NCT06553053","Acupuncture Reduces Relapse in Patients With Crohn's Disease: a Superiority Trial","Inclusion Criteria:\n\n1. patients with clinical diagnosis consistent with CD;\n2. aged 16-75;\n3. patients in remission (CDAI \\\u003C 150 and CRP \\\u003C 5mg\u002Fl, or Faecal calprotectin \\\u003C 50μg\u002Fg, or no ulcer under endoscopy);\n4. patients with frequent disease recurrences (≥2) in the past years;\n5. patients were not taking medication or were only taking one or more of the following drugs: \\[mesalazine (≤4g\u002Fd), prednisone (≤15mg\u002Fd), azathioprine (≤1mg\u002Fkg\u002Fd)\\] and prednisone and mesalazine were used for at least 1 month, while azathioprine was used for at least 3 months; or those who had poor response or loss of response to biological preparations (anti-TNF-α, IL-12p40, α4β7);\n6. those who have never experienced acupuncture;\n7. patients signing informed consent.\n\nExclusion Criteria:\n\n1. patients who are recently pregnant or in pregnancy or lactation;\n2. patients with serious organic diseases;\n3. patients diagnosed as psychosis;\n4. patients who suffer from multiple diseases and need to take other drugs for a long time, and may affect the observation of the efficacy of this trial;\n5. severe skin diseases (such as erythema nodosum, pyoderma gangrenosum, etc.), eye diseases (such as iritis, uveitis, etc.), thromboembolic diseases and other serious extraintestinal manifestations;\n6. there are serious intestinal fistula, abdominal abscess, intestinal stenosis and obstruction, perianal abscess, gastrointestinal hemorrhage, intestinal perforation and other complications;\n7. patients with short bowel syndrome who have undergone abdominal or gastrointestinal surgery in the past half a year;\n8. there are skin diseases or defects in the selected area of acupuncture and moxibustion that cannot be performed.","16 Years","75 Years",{"count":55,"type":21},106,[24],"The aim of this study was to further improve the clinical efficacy of acupuncture in delaying the clinical recurrence of CD and to explore the efficacy mechanism of acupuncture efficacy enhancement.",[59,60],"Crohn's Disease Relapse","Inflammatory Bowel Diseases","RECRUITING","2026-04-07",{"date":64,"type":37},"2026-04-13",{"date":66,"type":37},"2024-08-13",{"date":68,"type":21},"2028-12-31",{"name":43,"class":44},{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":77,"sex":16,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":45},"100597718","effectiveness-of-electrical-pudendal-nerve-stimulation-for-neurogenic-lower-urinary-tract-dysfunction-in-pediatric-tethered-cord-syndrome-post-surgery-100597718","NCT07062133","Effectiveness of Electrical Pudendal Nerve Stimulation for Neurogenic Lower Urinary Tract Dysfunction in Pediatric Tethered Cord Syndrome Post-Surgery","Clinical Evaluation of Electrical Pudendal Nerve Stimulation in Children With Postoperative Neurogenic Lower Urinary Tract Dysfunction Secondary to Tethered Cord Syndrome","Inclusion Criteria:\n\n* Children aged 3-18 years\n* Diagnosed with TCS (by spinal MRI) and NLUTD (by urodynamic study)\n* First-time detethering surgery completed\n* Be able to comply with acupuncture treatment and follow-up\n* Informed consent obtained from legal guardian\n\nExclusion Criteria:\n\n* Severe systemic diseases\n* Current urinary tract infection, severe VUR, hydronephrosis, structural obstruction\n* Prior aggressive urological surgery (e.g., augmentation cystoplasty)\n* Prior or planned pudendal\u002Fsacral nerve implant\n* Botulinum toxin injection within past 12 months\n* Planned reoperation within 6 months",true,"3 Years","18 Years",{"count":81,"type":21},50,[24],"The goal of this prospective observational study is to evaluate whether the addition of electrical pudendal nerve stimulation (EPNS) to standard conservative treatment can improve bladder function in pediatric patients with postoperative neurogenic bladder secondary to tethered cord syndrome . The study population consists of 50 children diagnosed with neurogenic bladder of various etiologies.\n\nThe main questions this study aims to answer are:\n\nDoes EPNS lead to significant improvement in neurogenic bladder symptom scores?\n\nHow does EPNS affect secondary clinical outcomes such as renal function, post-void residual volume, urinary leakage, and vesicoureteral reflux?\n\nResearchers will compare clinical indicators before and after the addition of EPNS, on the background of consistent conservative management, to assess its therapeutic contribution.\n\nParticipants will:\n\nReceive routine conservative therapy for neurogenic bladder (e.g., medications, bladder training)\n\nUndergo EPNS sessions over a specified treatment period\n\nBe evaluated using standardized scales and imaging or laboratory tests to monitor changes in bladder and renal function\n\nThe study will also explore whether treatment effects differ by underlying cause or symptom pattern.",[85],"Postoperative Neurogenic Lower Urinary Tract Dysfunction Secondary to Tethered Cord Syndrome",[87,88,89],"Neurogenic Lower Urinary Tract Dysfunction","Tethered Cord Syndrome","Electrical Pudendal Nerve Stimulation","2025-09-03",{"date":92,"type":37},"2025-09-04",{"date":94,"type":21},"2025-11-01",{"date":96,"type":21},"2027-03-31",{"name":43,"class":44},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":16,"minAge":79,"maxAge":53,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":121},"100437778","grain-moxibustion-treatment-on-insomnia-a-randomized-controlled-trial-100437778","NCT04980703","Grain Moxibustion Treatment on Insomnia: a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Meet the diagnostic criteria of insomnia;\n2. TCM syndrome differentiation belongs to deficiency of both heart and spleen;\n3. Male or female participants aged 18-75;\n4. Participants whose PSQI score is 5-15;\n5. The course of disease is more than 3 months;\n6. Participants who voluntarily agree with the investigation and sign a written informed consent form for the clinical trial.\n\nExclusion Criteria:\n\n1. Participants with mental retardation;\n2. Participants with serious cardiovascular diseases, liver, kidney and hematopoietic system diseases;\n3. Insomnia is caused by nervous system diseases (such as stroke, Parkinson's disease) or mental disorders (including depression or anxiety);\n4. Female participants who is pregnant or lactating;\n5. Participants with diabetes and sensory dysfunction.\n6. Participants with skin diseases of acupoints;\n7. Taking sedative hypnotics (including barbiturates, benzodiazepines, tranquilizers, diphenylmethane, etc) and other insomnia related drugs within 2 weeks before the trial;\n8. Participants with dependence on sleeping drugs;\n9. Participants suffering from malignant tumor, sequelae of severe cerebral apoplexy, organ failure and other major diseases that affect insomnia and therapeutic effect.",{"count":105,"type":21},102,[24],"This trial intends to observe the clinical efficacy and safety of grain moxibustion at Baihui(GV20), Xinshu(BL15) and Pishu(BL20) in the treatment of insomnia.",[109],"Sleep Initiation and Maintenance Disorders",[111,112],"moxibustion","insomnia","2025-05-13",{"date":115,"type":37},"2025-05-14",{"date":117,"type":21},"2027-07-01",{"date":119,"type":21},"2029-07-31",{"name":43,"class":44},2,{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":77,"sex":16,"minAge":52,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":22,"phases":132,"briefSummary":133,"conditions":134,"keywords":137,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":140,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":121},"100376922","effect-of-acupuncture-on-mild-to-moderate-active-crohns-disease-100376922","NCT04187820","Effect of Acupuncture on Mild to Moderate Active Crohn's Disease","Effect of Acupuncture on Crohn's Disease Via the Regulation of Trp-kyn Metabolism in Brain-gut Axis","Inclusion Criteria:\n\n1. aged 16-70;\n2. patients with mild or moderate active disease (150 ≤ CDAI \\\u003C 450);\n3. patients who are not responsive, intolerant, dependent or refused to use at least mesalazine, glucocorticoid, immunomodulator (azathioprine, methotrexate), anti TNF alpha preparation;\n4. patients were not taking medication or were only taking one or more of the following drugs: \\[prednisone ≤15mg\u002Fd, azathioprine (≤1mg\u002Fkg\u002Fd), methotrexate (≤15mg\u002Fw) or mesalazine (≤4g\u002Fd)\\] and prednisone was used for at least 1 month, while azathioprine, methotrexate or mesalazine was used for at least 3 months;\n5. those who did not use anti-TNF alpha and other agents within 3 months before entering the study;\n6. those who have never experienced acupuncture;\n7. patients signing informed consent.\n\nExclusion Criteria:\n\n1. patients who are recently pregnant or in pregnancy or lactation;\n2. patients with serious organic diseases;\n3. patients diagnosed as psychosis;\n4. patients who take antibiotics, probiotics, traditional Chinese medicine and other drugs at the same time, or who suffer from multiple diseases and need to take other drugs for a long time, and may affect the observation of the efficacy of this trial;\n5. severe skin diseases (such as erythema nodosum, pyoderma gangrenosum, etc.), eye diseases (such as iritis, uveitis, etc.), thromboembolic diseases and other serious extraintestinal manifestations;\n6. there are serious intestinal fistula, abdominal abscess, intestinal stenosis and obstruction, perianal abscess, gastrointestinal hemorrhage, intestinal perforation and other complications;\n7. patients with short bowel syndrome who have undergone abdominal or gastrointestinal surgery in the past half a year;\n8. there are skin diseases or defects in the selected area of acupuncture and moxibustion that cannot be performed.","70 Years",{"count":131,"type":21},60,[24],"To observe the clinical effect of acupuncture on Crohn's disease (CD) and its influence on brain function activity and the TRY-KYN metabolism level, and to screen the brain image markers of acupuncture on CD",[135,60,136],"Intestinal Disorder","Crohn Disease",[138,139],"acupuncture","Crohn's disease",{"date":115,"type":37},{"date":142,"type":37},"2019-06-01",{"date":144,"type":21},"2026-12-31",{"name":43,"class":44},""]